{"id":"3dbaaa87-16f6-530e-93d9-87e4565fb7f2","stable_key":"44737fa3-b335-53f4-a644-b9878d4416ac:creatine-human-gaa-feedback","predicate":"reduced","statement":"Plasma guanidinoacetate declined 10.6% with creatine versus a 3.7% rise with placebo over 12 weeks.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"8d8fcc2f-7317-50b2-aca0-fe771a998566","mechanism_event_label":"The human trial detected feedback on precursor production.","subject":{"id":"9f5df558-ed3d-5cda-b5ca-0f90f7aa6a8c","slug":"creatine","display_name":"Creatine","entity_type_key":"small_molecule"},"object":{"id":"b8913386-895e-56ed-9e60-c1217c59bc02","slug":"plasma-guanidinoacetate","display_name":"Plasma guanidinoacetate concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"8d8fcc2f-7317-50b2-aca0-fe771a998566","stable_key":"44737fa3-b335-53f4-a644-b9878d4416ac:creatine-human-gaa-feedback-event","event_type":"observed_intervention","label":"The human trial detected feedback on precursor production.","description":"Plasma guanidinoacetate declined 10.6% with creatine versus a 3.7% rise with placebo over 12 weeks.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"84053a83-8fcc-5068-8df9-58f7e97fad76","slug":"guanidinoacetate","display_name":"Guanidinoacetate","entity_type_key":"small_molecule"},"role":"measured_precursor","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"9f5df558-ed3d-5cda-b5ca-0f90f7aa6a8c","slug":"creatine","display_name":"Creatine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"b8913386-895e-56ed-9e60-c1217c59bc02","slug":"plasma-guanidinoacetate","display_name":"Plasma guanidinoacetate concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/creatine-research/26311810.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"055a97365d5a6d864e78eafcfa4a73bc8c425e240487580796a443cf8ef33a04\", \"start_char\": 0, \"end_char\": 2160, \"text_sha256\": \"055a97365d5a6d864e78eafcfa4a73bc8c425e240487580796a443cf8ef33a04\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Twelve-week randomized placebo-controlled trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Creatine 3 g/day, folic acid 400 micrograms/day, both, or placebo; analyzed groups 101, 153, 103 and 101 respectively","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Group-average effects and exploratory within-person associations are distinct. No general claim of restored methylation or reduced disease risk.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Creatine research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"creatine","display_name":"Creatine","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Bangladeshi adults","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The human trial detected feedback on precursor production.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[creatine-p26311810] Low-Dose Creatine Supplementation Lowers Plasma Guanidinoacetate, but Not Plasma Homocysteine, in a Double-Blind, Randomized, Placebo-Controlled Trial. (2015). https://pubmed.ncbi.nlm.nih.gov/26311810/ DOI: 10.3945/jn.115.216739","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Plasma metabolites","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"7ff09cd4-8b19-5592-b232-de73143ec07c","evidence_kind":"source_excerpt","locator":"Lines 724-735","start_line":724,"end_line":735,"excerpt":"### creatine-human-gaa-feedback\nPlasma guanidinoacetate declined 10.6% with creatine versus a 3.7% rise with placebo over 12 weeks.\nCondition category: normal\nnutrient_topic: Creatine research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The human trial detected feedback on precursor production.\norganism: Bangladeshi adults\ntissue_or_cell_type: Plasma metabolites\nexperimental_model: Twelve-week randomized placebo-controlled trial\nlimitations: Group-average effects and exploratory within-person associations are distinct. No general claim of restored methylation or reduced disease risk.\nexposure: Creatine 3 g/day, folic acid 400 micrograms/day, both, or placebo; analyzed groups 101, 153, 103 and 101 respectively\nevidence_span: {\"source_cache\": \"artifacts/creatine-research/26311810.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"055a97365d5a6d864e78eafcfa4a73bc8c425e240487580796a443cf8ef33a04\", \"start_char\": 0, \"end_char\": 2160, \"text_sha256\": \"055a97365d5a6d864e78eafcfa4a73bc8c425e240487580796a443cf8ef33a04\"}\n[creatine-p26311810] Low-Dose Creatine Supplementation Lowers Plasma Guanidinoacetate, but Not Plasma Homocysteine, in a Double-Blind, Randomized, Placebo-Controlled Trial. (2015). https://pubmed.ncbi.nlm.nih.gov/26311810/ DOI: 10.3945/jn.115.216739","model_system":"Twelve-week randomized placebo-controlled trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [creatine-p26311810] Low-Dose Creatine Supplementation Lowers Plasma Guanidinoacetate, but Not Plasma Homocysteine, in a Double-Blind, Randomized, Placebo-Controlled Trial. (2015). https://pubmed.ncbi.nlm.nih.gov/26311810/ DOI: 10.3945/jn.115.216739","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"70358046-c5c3-5e9a-9fc9-eb01c3fff88b","stable_key":"import-44737fa3-b335-53f4-a644-b9878d4416ac","title":"Creatine: synthesis, transport, phosphocreatine energetics and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"548237d3e98a73a7dc02181807921fdd8b902adcee46248792258a761593eda9","revision_id":"88738255-8028-52fb-9c12-0fe92d8ce367","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}